Dementia is a neurologic condition manifested by a substantial decline in multiple cognitive abilities that collectively render a person unable to function at expected levels and progressively impede independent ability to perform everyday activities. For decades, public health officials have warned of the coming tsunami of Alzheimer disease (AD), and dementia has even been characterized as the dominant scourge of modern times, replacing cancer. Recently, hopeful signs have appeared, including reports from some longitudinal research studies that incidence of dementia is declining, and from the federal government that research funding for AD and other dementias will approach $1 billion USD in 2017.

The consequential nature of dementia cannot be underestimated. Although not often conceptualized as such, dementia is a terminal disorder. According to the 2015 annual statistics available from the Alzheimer’s Association, 1 in 9 Americans aged 65 and older has AD and 1 in 3 older adults who dies in a given year has been diagnosed with AD or another dementing disorder. It is estimated that 14.7% of people older than 70 in the United States have dementia. AD is listed officially as the sixth leading cause of death in the United States. Further, the monetary cost of dementia in the United States ranges from $159 to $215 billion annually, making it more expensive than heart disease or cancer. In 2014, unpaid caregivers provided nearly 18 billion hours of care to people with dementia, often at non-trivial cost to their own health and well-being.

After passage of the National Alzheimer’s Project Act of 2011, an Advisory Council for Alzheimer’s Research, Care, and Services convened to advise the Department of Health and Human Services; the National Plan it produced in 2012 featured a prominent call for quality measures for the care of patients with dementia. Measurement of quality in care practices and services for persons with dementia and their caregivers remained an integral part of the Advisory Council’s work in 2016.

The first set of dementia management quality measures was developed and published in 2013 by the American Academy of Neurology (AAN) under the American Medical Association (AMA) Physician Consortium for Performance Improvement (PCPI) performance measurement development model. Previ

sely convened by the AMA, the PCPI Foundation is now an independent foundation comprising multiple organizations focusing on the advancement of measurement science, quality improvement, and clinical registries. The Centers for Medicare and Medicaid Services (CMS) incorporated select measures into the Physician Quality Reporting System (PQRS), at that time the main quality reporting program through which eligible professionals and group practices reported information on the quality of care provided to their patients with Medicare. Measures may be incorporated into CMS’ Merit-based Incentive Payment System (MIPS), which replaced PQRS in 2017.

In 2014, the AAN and the American Psychiatric Association (APA) assumed joint stewardship of the dementia management measurement set, with the exception of the Cognitive Assessment measure, for which the PCPI retained stewardship. In 2015, the AAN and the APA formed a multidisciplinary Workgroup to convene the first update of the dementia management measurement set. Following a transparent and inclusive process, the AAN Quality and Safety Subcommittee reviewed and approved a final set of quality measures for the care of people with dementia. This document presents the measurement set, which is now an official product of the AAN, and is intended to help improve the quality of care for people with dementia. The AAN is grateful to the many organizations and individuals who supported the development and implementation of this important measurement set.

Glossary

AAN = American Academy of Neurology; AD = Alzheimer disease; AMA = American Medical Association; APA = American Psychiatric Association; BPSD = behavioral and psychiatric symptoms; CMS = Centers for Medicare and Medicaid Services; DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, 5th edition; MCI = mild cognitive impairment; MIPS = Merit-based Incentive Payment System; NQF = National Quality Forum; PCPI = Physician Consortium for Performance Improvement; PQRS = Physician Quality Reporting System.

From the Department of Neurology (A.E.S.), SUNY Upstate Medical University, Syracuse; Department of Psychiatry (J.N.), Well/Cornell Medical College, New York, NY; Absher Neurology, PA (J.A.); Alliance for Neuro Research, LLC (J.A.); University of South Carolina School of Medicine (J.A.); Greenville, Via College of Osteopathic Medicine (J.A.); Spartanburg, SC; American Academy of Neurology (A.B.); Minneapolis, MN; American Psychiatric Association (S.S.), Arlington, VA; Sheppard Pratt Health System (R.R.), Towson, Department of Psychiatry (R.R.), University of Maryland School of Medicine; and Department of Psychiatry (R.R.), John Hopkins University School of Medicine, Baltimore, MD.

This special article is published simultaneously in The American Journal of Psychiatry and Neurology®.

Approved by the AAN Quality and Safety Subcommittee on April 7, 2016; AAN Practice Committee on May 5, 2016; and AAN Board of Directors on July 26, 2016. Approved by the APA Performance Measurement Committee on May 25, 2016; APA Council on Geriatric Psychiatry and APA Council on Quality Care Committee on July 6, 2016; and APA Executive Committee of Board of Trustees on July 28, 2016.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Group to improve the original dementia management quality measurement set and to identify opportunities to define new quality measures to operationalize delivery of the best possible care for patients with dementia. The Work Group proceeded from the understanding that dementia is a syndrome rather than a disease. Herein, and also throughout the referenced measurement set, dementia is used as an umbrella phrase to encompass the numerous diseases and disorders that cause the symptoms of cognitive and functional decline constituting the dementia syndrome. This update applies to patients in whom the dementia syndrome and its underlying dementing disorder have been identified through a rigorous diagnostic evaluation. Quality measures for the approach to dementia diagnosis and for the characterization of prodromal states such as mild cognitive impairment (MCI) are important and urgently needed, but they lie outside the scope of this measurement set.

**OPPORTUNITIES FOR IMPROVEMENT**

Providing health care services to patients with dementia poses unique challenges. A key prerequisite for the development of a measure is confirmation that provider performance is not yet ideal, constituting continued room for improvement. A single measurement set cannot possibly capture all aspects of providing care for patients with dementia and their caregivers. This update focuses on key thematic elements in caring for patients with dementia, regardless of the underlying dementing disease. The original Cognitive Screening measure was unavailable for update by the Work Group. This should in no way be interpreted as diminishing the importance of annual cognitive assessment, which remains an essential component of quality dementia care management. Indeed, the PCPI opted to retain stewardship of the cognitive assessment measure, given its prominence in the measurement landscape. As such, the PCPI will ensure that the measure remains clinically relevant and consistent with the most current evidence, and that the specifications adhere to current industry standards. The measure was recently approved for trial use by the National Quality Forum (NQF), and the PCPI will continue to pursue testing data to facilitate eventual full endorsement by the NQF.

The Work Group developed measures to address 9 areas or processes in which quality of care could be improved.

**Disclosure of diagnosis.** In this setting, disclosure refers to both the diagnosis of the dementia syndrome and an explanation of the specific disease identified through prior diagnostic evaluation as the most likely cause of the dementia. The diagnosis of AD, the disease most commonly causing the dementia syndrome, is disclosed to patients or caregivers less than 50% of the time. Withholding the diagnosis of dementia and its underlying specific disease unfairly disadvantages many patients and their families in accessing available services and obtaining assistance to plan for the future.

**Education and support of caregivers.** Persons with dementia become highly dependent on others, particularly as cognitive functioning worsens and behavioral symptoms emerge. Whether taken on by a single individual or shared among several members of the broader support community for the person with dementia, the caregiver role can be extremely stressful and takes a toll on general and mental health. Clinicians have knowledge of methods and resources to assist caregivers, and sharing this knowledge is an essential aspect of providing good clinical care.

**Functional assessment.** In routine practice, persons with dementia may not be assessed regularly for changes in their ability to perform both basic and instrumental activities of daily living. Frequent and comprehensive assessments allow health care providers to track these changes and make timely interventions aimed at supporting function or mitigating disability.

**Screening for behavioral and psychiatric symptoms.** Behavioral and psychiatric symptoms, including depression, are common in dementia, major sources of disability and distress, and frequently neither detected nor appropriately treated. Regular screening for and management of these symptoms will improve the quality of life for patients and reduce caregiver burden.

**Screening for safety concerns.** Screening for safety concerns is a major unmet need for patients with dementia. Injuries associated with falls, accidents, and aggression have serious adverse effect on the quality of life of patients and caregivers. It is possible to reduce the risk of these outcomes through simple preventive measures. Opportunities to introduce these preventive measures may be overlooked if health care providers fail to screen for safety risks, paying specific attention to discrete risk domains.

**Screening for driving safety.** The onset of dementia often correlates with deterioration in driving skill and increased risk of accidents. Health care providers are often reluctant to raise the issue of driving safety because they feel incompetent to assess it and because patients frequently resist such discussions. Screening for driving safety at regular intervals will identify potential deficits and create opportunities to review reasonable options for remaining mobile in the community.

**Advance care planning.** Growing evidence indicates that patients want to engage in advance care planning.
to ensure that their end-of-life wishes are met, but few patients with dementia are engaged in these discussions. Persons with dementia without advance directives face increased risks of burdensome end-of-life transitions.

**Screening for pain.** Pain is frequently unrecognized, undertreated, and poorly managed in elderly persons, particularly those with dementia.

**Treatment of dementia.** Guideline-adherent pharmacologic treatment of dementia occurs in as few as one-third of primary care practices.

**METHODS**

The AAN and APA formed the Work Group for the purpose of updating and modifying the original dementia management quality measure set using the AAN measure development process. Details of the full measure development process are available online. The AAN and APA leadership team sought a broad representation of key stakeholders. Members were selected through a competitive process by the leadership team evaluating relevant and substantive experience in quality measurement, dementia care, or both. The selected Work Group comprised 26 members from 21 organizations (a list of members and contributing organizations follows this article), including physician, patient, caregiver, advanced practice provider, psychologist, payer, and nursing representatives. Insights provided by patient and caregiver representatives proved invaluable. All members disclosed potential conflicts of interest and were instructed to abstain if a potential conflict could be perceived during voting.

The Work Group’s overarching priority was to conceptualize the best possible care for patients with dementia and their caregivers and to operationalize optimal processes for delivering such care. Candidate measures were reviewed and edited prior to a vote to approve, reject, or abstain from moving the proposed measure forward. Measures were refined through an iterative, consensus-based process before, during, and after the in-person meeting. Within this overall construct, measure feasibility and usability were given high priority, with the goal of minimizing reporting burdens. During this process, the Work Group also reviewed each of the original measures, evaluating whether current evidence still supported them, whether gaps in care continued, and whether links to desired outcomes have been described. This measurement set has been approved by the Work Group, the AAN Quality and Safety Subcommittee, the AAN Practice Committee, the AAN Institute Board of Directors, the APA Performance Measurement Committee, the APA Council on Geriatric Psychiatry, the APA Council on Quality Care, the APA Joint Reference Committee, and the APA Board of Trustees.

Appendix e-1 at Neurology.org provides further information on the measure development process and evidence used for these measures. In addition, individual measure specifications are included with numerator, denominator, exceptions, and time frame for the measure. Denominator exceptions occur when a clinical factor necessitates removal of the patient from the denominator, and they require a clear rationale for exception on the grounds of medical, patient, or system reasons. When applicable, explicit exceptions are noted with rationale; precise specification of exceptions should foster ease of use in future conversion to electronic measures. In cases where assessment tools (i.e., screening tools for behavioral and psychological symptoms of dementia [BPSD]) are required to satisfy the measure, options for reliable and validated tools are provided in a nonprescriptive manner. Efforts were made to harmonize updated measures with extant measures whenever possible; details on measure harmonization are included in the individual measure specifications.

The AAN and APA will update these measures on an ongoing basis every 3 years, allowing the measurement set to provide a working framework for measurement, rather than a long-term mandate.

**RESULTS**

The updated measurement set addresses a small but important subset of the priorities inherent in high-quality dementia care. The co-chairs and facilitators reviewed 249 abstracts, identifying 23 guidelines to serve as the measures’ evidence base. The Work Group ranked 11 candidate measures for review at the face-to-face meeting, where, after review of evidence and gaps in care, 9 measures were finalized. The public comment period resulted in over 150 comments from 25 individuals or organizations. Each measure is designated for both quality improvement and accountability purposes. Each measure applies at the individual practitioner (physician or other health care professional), practice, and system (hospital or health care) level, and is applicable in outpatient, inpatient, emergency department or urgent care, or postacute care facility settings. Table 1 includes measure titles and a brief description of each of the 9 process measures; full measure specifications are available in appendix e-1.

The Work Group review resulted in decisions to retire or reconfigure 3 measures (table 2), to reaffirm 6 with modifications, and to develop and approve 3 new measures. Consensus supported retirement of the staging measure on the grounds that dementia stages constitute artificial constructs with little intrinsic meaning. The Work Group concluded that there is value in continued assessment of disease progression, but patients and caregivers may be better served simply by hearing whether dementia is mild, moderate, or severe. This rather more qualitative algorithm, while still a staging of sorts, is less formal and has face validity that is easy to grasp for clinician and caregiver alike. Functional assessment is retained in the new suite of measures. The depression screening and management of neuropsychiatric symptoms measures were subsumed into an updated measure on screening and management of the BPSD of dementia.

Six measures were retained with modifications. For example, in the driving safety measure, the exception for patients with dementia who had already stopped driving was removed in response to reports that the exception had caused confusion in pay-for-reporting programs. In the caregiver education measure, new exceptions were created for patients without caregivers, caregivers with prior training or certification, and patient/caregiver dyads already connected with existing supports. For the functional status measure, additional clarity was provided on how to meet assessment requirements. The safety measure
Table 1  2015 Dementia management measurement set update

<table>
<thead>
<tr>
<th>Measure title</th>
<th>Measure description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disclosure of dementia diagnosis*</td>
<td>Percentage of patients with a diagnosis of a qualifying dementing disorder or disease whose diagnosis has been disclosed to them and, if available, their primary caregiver</td>
</tr>
<tr>
<td>Education and support of caregivers for patients with dementia</td>
<td>Percentage of patients with dementia whose caregivers were provided with education on dementia disease management and health behavior changes and were referred to additional resources for support in the last 12 months</td>
</tr>
<tr>
<td>Functional status assessment for patients with dementia</td>
<td>Percentage of patients with dementia for whom an assessment of functional status was performed at least once in the last 12 months</td>
</tr>
<tr>
<td>Screening and management of behavioral and psychiatric symptoms associated with dementia (BPSD)</td>
<td>Percentage of patients with dementia for whom there was a documented screening for behavioral and psychiatric symptoms, including depression, and for whom, if screening positive, there was also documentation of recommendations for management in the last 12 months</td>
</tr>
<tr>
<td>Safety concern screening and follow-up for patients with dementia</td>
<td>Percentage of patients with dementia or their caregivers for whom there was a documented safety screening in 2 domains of risk, dangerousness to self or others and environmental risks, and for whom, if screening positive, there was documentation they were provided with recommendations for their mitigation, which may include referral to other resources, in the last 12 months</td>
</tr>
<tr>
<td>Driving screening and follow-up for patients with dementia</td>
<td>Percentage of patients with dementia for whom there was a documented screening for driving risks and for whom, if screening positive, there was also documentation they were informed of alternatives to driving in the last 12 months</td>
</tr>
<tr>
<td>Advance care planning and palliative care counseling for patients with dementia</td>
<td>Percentage of patients with dementia who have an advance care plan or surrogate decision-maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision-maker or provide an advance care plan and percentage of patients with dementia or their surrogate decision-maker who received comprehensive counseling regarding ongoing palliation and symptom management and end-of-life decisions within 2 years of initial diagnosis or assumption of care</td>
</tr>
<tr>
<td>Pain assessment and follow-up for patients with dementia*</td>
<td>Percentage of patients with dementia who underwent documented screening for pain symptoms at every visit and if screening positive also had a documentation of a follow-up plan</td>
</tr>
<tr>
<td>Pharmacologic treatment of dementia*</td>
<td>Percentage of patients with dementia or their caregivers for whom available guideline-appropriate pharmacologic treatment options and nonpharmacological behavior and lifestyle modifications were discussed at least once in the last 12-month period</td>
</tr>
</tbody>
</table>

* New measure added in 2015.

Table 2  2009 Dementia management quality measures\(^{19}\)

| Measure 1: Staging of dementia (retired 2015)                      |
| Measure 2: Cognitive assessment (Physician Consortium for Performance Improvement maintains stewardship of this measure) |
| Measure 3: Functional status assessment                           |
| Measure 4: Neuropsychiatric symptom assessment                    |
| Measure 5: Management of neuropsychiatric symptoms (retired 2015) |
| Measure 6: Screening for depressive symptoms (retired 2015)       |
| Measures addressing safety                                       |
| Measure 7: Counseling regarding safety concerns                   |
| Measure 8: Counseling regarding risks of driving                 |
| Measures addressing underuse of patient-centered care strategies  |
| Measure 9: Palliative care counseling and advance care planning   |
| Measure 10: Caregiver education and support                       |

was modified to specify dual risk domains related to self/others or the environment. The previously separate measures for assessment and management of neuropsychiatric symptoms were unified in a single measure devoted to evaluation and management of BPSD; this measure also incorporated the previous stand-alone measure on depression screening.

Finally, 3 new measures were developed. The first addresses disclosure of the dementia diagnosis, for both the dementia syndrome and the most likely etiologic dementing disorder. The second focuses on assessing the vulnerable population of patients with dementia for pain. The third is a measure for treatment, emphasizing pharmacologic treatment, when appropriate, within treatment rubrics that also by necessity incorporate nonpharmacologic behavioral and lifestyle modifications. This measure encompasses pharmacologic and nonpharmacologic treatment strategies because Food and Drug Administration–approved pharmacologic treatments are available for only a select subset of dementing diseases and even these are symptom- rather than disease-modifying agents.

The Work Group discussed, but opted not to develop, several measures or measure components. Additional elder abuse and violence screening were considered as potential components of the safety measure, but it was ultimately determined that these concerns were beyond the scope of the safety measure and...
The Work Group also warrants the goal of quality measures is to especially as it performance, including measures endorsed by NQF.

Several potential outcome measures were discussed for possible development and inclusion in the final measure set. The Work Group considered several intermediate outcome measures (proportion of patients identified as at-risk drivers who had ceased driving, proportion of patients for whom advance care plans were developed, proportion of patients not on anticholinergic drugs). Ultimately, it was concluded that the inexorably neurodegenerative and terminal nature of dementia and its constituent diseases makes specification of rigorous outcome measures with appropriate risk adjustment difficult at this time. Several of the measures construed herein as process measures (i.e., functional status, BPSD assessment) are included in similar form in the Dementia Outcomes Set using Patient-Reported Outcome measurement tools recently published by the International Consortium for Health Outcomes Measurement.

As noted, this update focuses on the management of dementia and what are termed major neurocognitive disorders in DSM-5. As a result, the measurement set does not apply to individuals diagnosed with MCI, delirium, amnestic disorders, alcohol-induced persisting amnestic disorders, postconcussion syndrome, encephalopathy, memory loss, alteration of consciousness, and other unspecified persistent mental disorders. The full set of dementing disorders to which the update does apply is found in appendix e-1 of the measurement set document.

DISCUSSION The goal of quality measures is to guide their users to evidence-based improvements in care and, eventually, health care outcomes. The measures described herein offer a broad scope of processes necessary to improve the care of patients with dementia. It is the hope of the Work Group that implementation of the measures will lead to measurable improvements in the care of this most vulnerable population. At present, there are no disease-modifying medications for any of the diseases that cause the dementia syndrome, so many of the principles underlying good care in patients with dementia focus on nonpharmacologic aspects. The measures are unusual for the degree of emphasis they accord to the caregivers, indeed often conceptualizing the patient/caregiver dyad as the unit of treatment. This focus is novel and relatively uncommon in quality measures. The focus on communication represents another important shift toward more holistic care concepts than is currently common in most quality measures, yet is essential to good care for patients with dementia.

Clinicians should also be cognizant of reasonable performance expectations: there is no expectation that any provider will achieve instant 100% satisfaction of any, let alone all, of the measures. Such expectations miss the point that quality measurement is but the first step in quality improvement. Taking the time to assess and report one’s performance is a crucial first step; providers should not fear being dinged if they do not achieve 100% immediate fulfillment of the measurement set. Only by measuring one’s performance can one become aware of areas in need of improvement and then initiate the changes necessary to achieve better care. Clinicians should implement these measures in advance of payment mandates, such as MIPS, to ensure readiness and to ensure that the highest quality of care is being provided.

Several limitations associated with the current Update provide direction for future Work Groups. First, given anticipated changes in the dementia care landscape, increased participation from social workers, emergency clinicians, and disease-specific advocacy groups will be important considerations for future Work Groups. Second, the development of outcome measures, with the necessary attendant schemata for risk adjustment, will be a future focus. Third, measures to address coordination of care—especially as it relates to transitions between care levels—warrant future attention if cross-cutting measures in this area prove insufficient. Finally, future updates will review previously proposed measures for emergent relevance within a shifting care landscape.

This update represents the current state of evidence. Given increased funding and research, it is hoped that care for patients with dementia will evolve rapidly in coming years. The Work Group recognizes that quality care for patients with dementia is often still conducted in a precarious environment of inadequate home-based care and high-risk transitions between levels of care, amid numerous other challenges not limited to care models favoring procedures over so-called cognitive care, inadequate social support systems, and the long-term viability of Medicare. The AAN and APA will continue to revise the measurement set as needed to address areas in which improvement can and should occur. Clinicians must remain vigilant to ensure care being provided is of the highest quality.

AUTHOR CONTRIBUTIONS Dr. Sanders contributed to study concept and design, acquisition of data, analysis and/or interpretation of data, drafting/revising the manuscript, critical revisions of the manuscript for important intellectual content, and study supervision including responsibility for conduct of research.
and final approval. Dr. Nininger contributed to study concept and design, acquisition of data, analysis and/or interpretation of data, critical revisions of the manuscript for important intellectual content, and study supervision including responsibility for conduct of research and final approval. A. Bennett contributed to study concept and design, acquisition of data, analysis and/or interpretation of data, critical revisions of the manuscript for important intellectual content, and study supervision including responsibility for conduct of research and final approval. S. Shugarman contributed to study concept and design, acquisition of data, analysis and/or interpretation of data, drafting/revising the manuscript, critical revisions of the manuscript for important intellectual content, and study supervision including responsibility for conduct of research and final approval. Shugaraman contributed to study concept and design, acquisition of data, analysis and/or interpretation of data, drafting/revising the manuscript, critical revisions of the manuscript for important intellectual content, and study supervision including responsibility for conduct of research and final approval. Dr. Roca contributed to study concept and design, acquisition of data, analysis and/or interpretation of data, drafting/revising the manuscript, critical revisions of the manuscript for important intellectual content, and study supervision including responsibility for conduct of research and final approval.

ACKNOWLEDGMENT
The authors thank all the Dementia Management Update Quality Measurement Set Work Group members for their dedication, time, energy, contributions and work that supported the development of this manuscript: Amy E. Sanders, MD, MS, FAAN (American Academy of Neurology); Robert Roca, MD (American Psychiatric Association); Piero Antuono, MD (American Academy of Neurology); Kelly Sullivan, PhD (American Academy of Neurology); Karl Goodkin, MD, PhD, DFAPA (American Psychiatric Association); Donovan Maust, MD, MS (American Psychiatric Association); Michael Lubin, MD, MACP (American College of Physicians); Sam Fazio, PhD (Alzheimer’s Association); Ann Knutson (Alzheimer’s Association); Robert O’Keefe, MA (Alzheimer’s Association); Eric Tangalos, MD, FACP, AGSF, CMD (AMD-DS-The Society for Post-Acute and Long-Term Care Medicine); Glenn Smith, PhD (American Academy of Clinical Neuropsychology and American Psychological Association); Brian Unwin, MD, FAAP (American Academy of Family Physicians); Joseph Shega, MD (American Academy of Hospice and Palliative Medicine); Dale Strasser, MD (American Academy of Physical Medicine and Rehabilitation); Michele Grigatis, DNP, FNP-BC, CNRN (American Association of Neuroscience Nurses); Jerry Johnson, MD (American Geriatrics Society); Mary Kathleen Owens, RN MSN, C-NE, RAC-CT (American Health Care Association and Gerontological Advanced Practice Nurses Association); Catherine Fiersol, PhD, OTR, FAOTA (American Occupational Therapy Association); Lise McCarthy, PT, DPT, GCS (American Physical Therapy Association); Kathleen Welch-Bohmer, PhD, ABPP (American Psychological Association); David Webster, MD, MBA (Humana); James Galvin, MD, MPH, FANA (Lewy Body Dementia Association); Daniel Marson, PhD, JD (National Academy of Neuropsychology); Richard Fortinsky, PhD (The Gerontological Society of America); Maren McGuire, MD (Veteran’s Affairs); John Ahsher, MD (American Academy of Neurology Facilitator); James Nininger, MD (American Psychiatric Association Facilitator); Amy Bennett, JD (American Academy of Neurology Staff); Gina Gjoervad (American Academy of Neurology Staff); Erin Hagen (American Academy of Neurology Staff); Becky Schierman, MPH (American Academy of Neurology Staff); Samantha Shugaraman, MS (American Psychiatric Association Staff); and Kristen Kroeger (American Psychiatric Association Staff). The authors also thank Jean O’Keefe for participation and the individuals and organizations who offered public comments.

STUDY FUNDING
No targeted funding reported.

DISCLOSURE
A. Sanders is the Site PI at Upstate for the TCAD/Noble clinical trial, sponsored by the Alzheimer’s Disease Cooperative Study and Toyama Chemical Company, Ltd. J. Nininger reports no disclosures relevant to the manuscript. J. Ahsher is a member of the South Carolina Alzheimer’s Association Board of Directors. A. Bennett, S. Shugarman, and R. Roca report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Received July 28, 2016. Accepted in final form February 17, 2017.

REFERENCES


